Phase 1 Study of MPC-6827 and Carboplatin in Recurrent/Relapsed Glioblastoma Multiforme

Inclusion Criteria: * Histologically proven WHO Grade IV glioblastoma multiforme at time of diagnosis or relapse * Prior treatment with radiotherapy and temozolomide * Evidence of measurable recurrent or residual primary tumor by contrast-enhanced MRI * Be a minimum of 4 weeks since prior surgical resection, major surgical procedure, radiation therapy or cytotoxic chemotherapy (6 weeks since prior BCNU or CCNU) * Have a Performance Scale of Karnofsky \> 60%, ECOG \< 2 or WHO \< 2 * If steroids are needed, be on a stable or decreasing dose of steroids for at least 1 week Exclusion Criteria: * Hypersensitivity to Cremophor EL * Have evidence of current/active intratumor hemorrhage by MRI * Have greater than second relapse * Have had prior treatment with platinum-based chemotherapy * Have cardiovascular disease * Have cerebrovascular disease * Have uncontrolled hypertension * Have a cardiac ejection fraction \< 50% * Have Troponin-I elevated above the normal range